US-based medical device company CurvaFix has received the US Food and Drug Administration (FDA) 510(k) clearance for its CurvaFix Low Profile System.
The system is designed to enhance the treatment of pelvic fractures, facilitating early mobility, a crucial factor in patient recovery and quality of life restoration.
It aims to address complex surgical challenges, such as pathological bones and narrow pelvic corridors.
Also, the system reduces pain and accelerates recovery compared to traditional methods, said CurvaFix.
CurvaFix CEO Mark Foster said: “CurvaFix continues to revolutionise pelvic fracture fixation with the launch of our Low-Profile System.
“This new system reflects four years of clinical use and thousands of successful implants, coupled with direct feedback from orthopaedic trauma surgeons.
“The result is a familiar, intuitive implantation technique designed to address the complexities of pelvic fracture fixation, while also allowing streamlined implant removal if required.”
The key features of the Low Profile System include a 65% smaller head geometry, enhanced compression capabilities, and extended implant lengths up to 210mm.
It features a patented lock technology for improved confirmation during procedures.
Clinical use of CurvaFix technology suggests it provides robust fixation by conforming to the natural curvature of the pelvis.
Orthopaedic trauma surgeon Samir Mehta said: “CurvaFix Low Profile advances surgeons’ ability to address surgical scenarios well beyond the reach of traditional hardware.
“It has transformed how we manage these injuries, delivering exceptional outcomes, an excellent safety profile, and early weight bearing for patients facing these difficult fractures.
“The new platform takes CurvaFix technology to the next level, offering improvements that directly benefit both patients and surgeons.”
